Amneal Pharmaceuticals and Intrexon Corporation today announced the formation of an Exclusive Channel Collaboration (ECC) to develop an improved production process for a complex active pharmaceutical ingredient (API). The companies will continue to explore other similar opportunities for collaboration in the future.
The vast majority of active pharmaceutical ingredients are currently produced through a series of complex chemical processes. The goal of the collaboration is to develop a biological process for a targeted API production that may reduce the cost of production. The collaboration will leverage Intrexon's proprietary UltraVector platform as well as the company's suite of integrated synthetic biology technologies.
Chintu Patel, Co-CEO and Chairman, of Amneal said, "Intrexon has an impressive track record developing the full potential of synthetic biology. This is an exciting new proposition for the expansion of our generic pharmaceutical development capabilities. We are hopeful that success on this project is the beginning of an ongoing relationship that will grow our pipeline and cultivate a broader, more robust offering for our customers." Samuel Broder, M.D., Chairman of Intrexon's Health Sector and former Director of the National Cancer Institute, said, "Amneal is a leader in high quality generic pharmaceuticals. Their experience combined with Intrexon's synthetic biology technology has the potential to drive a complex, multi-step chemical process toward a new era of more affordable drugs produced through biology-enabled production methods."